Gilead Sciences number of employees

Gilead Sciences reported 17,000 employees at December 31, 2025 in its latest annual report, down 600 (3.4%) on the year before. That compares with 14,400 at December 31, 2021. Revenue per employee was $1.7m.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	17,000	−600 (3.4%)	$1.7m	10-K, filed February 24, 2026
December 31, 2024	17,600	−400 (2.2%)	$1.6m	10-K, filed February 28, 2025
December 31, 2023	18,000	+1,000 (5.9%)	$1.5m	10-K, filed February 23, 2024
December 31, 2022	17,000	+2,600 (18.1%)	$1.6m	10-K, filed February 22, 2023
December 31, 2021	14,400	—	$1.9m	10-K, filed February 23, 2022

What the annual reports say

As of December 31, 2025, Gilead had approximately 17,000 employees 2025 annual report
As of December 31, 2024, Gilead had approximately 17,600 employees. 10 Total Rewards Gilead’s Total Rewards portfolio is a competitive, robust benefits package that is designed to optimize our employees’ performance and support their wellbeing, allowing them to focus on mission-critical work. 2024 annual report
As of December 31, 2023, Gilead had approximately 18,000 employees, and Gilead’s global workforce was approximately 53% female. 2023 annual report
As of December 31, 2022, Gilead had approximately 17,000 employees, and Gilead’s global workforce was approximately 53% female. 2022 annual report
As of December 31, 2021, Gilead had approximately 14,400 employees, and Gilead’s global workforce was approximately 52% female and 48% male. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: GILD vs REGN ABBV vs GILD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Gilead Sciences's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gilead Sciences.